Company intelligence / Profile preview

ChemRar High-Tech Center

Khimki, Moscow Oblast, Russiatrial.medpath.com ↗

Ownership: Private
Development stage: Phase 3

Overview

ChemRar has developed multiple drugs including Avifavir (first favipiravir-based drug approved for COVID-19 treatment) and has several compounds in various clinical stages

Therapeutic areas: PsychiatryCardiovascularOncologyNeurologyInfectious Diseases
Modalities: Small moleculesBiotechnological medicinesVaccines
Industry: Biotech

Drug pipeline

1 asset

Aviandr

Partnerships

Russian Direct Investment Fund (RDIF)

Beyond the preview

Go deeper on ChemRar High-Tech Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemRar High-Tech Center.

Explore the full profile